Regulatory, legislative, and policy updates with anticoagulant use.
Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making organizations have intervened with the aim of improving patient outcomes, ensuring patient safety, and reducing costs. There have been a number of recent developments in surveillance, litigation, and regulatory oversight that clinicians should recognize. In this review article we summarize key updates related to the management of anticoagulant therapy as it relates to thrombosis prevention and treatment.
Department of Pharmacy Services, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA, jfanikos@partners.org.
John
J
Fanikos
Leo F
LF
Buckley
Ahmed
A
Aldemerdash
Kimberly J
KJ
Terry
Gregory
G
Piazza
Jean M
JM
Connors
Samuel Z
SZ
Goldhaber
D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D007880:Legislation, Drug; D013923:Thromboembolism / Q000188:drug therapy*; D014481:United States
D000925:Anticoagulants